RECRUITINGOBSERVATIONAL
Prospective Cohort Study in Patients With NAFLD
Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
About This Trial
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with diagnosed by tissue sample (biopsy-confirmed) fatty liver disease
Who Should NOT Join This Trial:
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone).
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion criteria:
* Patients with histologically confirmed fatty liver disease
Exclusion criteria:
* History of significant alcohol consumption
* Viral hepatitis
* Autoimmune hepatitis
* Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
* Hepatotoxic medication (e.g. amiodarone).
Locations (1)
University Hospital Zurich, Endocrinology and Diabetology
Zurich, Canton of Zurich, Switzerland